Featured Research

from universities, journals, and other organizations

Radium-223 dichloride in prostate cancer: Major added benefit for certain patients

Date:
April 3, 2014
Source:
Institute for Quality and Efficiency in Health Care
Summary:
Radium-223 dichloride has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases. In an early benefit assessment, researchers examined whether this new drug offers an added benefit over the appropriate comparator therapy. No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal. Hence an added benefit is not proven for this comparison.

Radium-223 dichloride (radium-223 for short, trade name: Xofigo) has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal. Hence an added benefit is not proven for this comparison.

Depending on the patients' age and the concomitant treatment (with/without bisphosphonates), there is an indication of major and an indication of minor added benefit of radium-223 compared with best supportive care (BSC).

No valid data for the comparison with docetaxel combination therapy

Radium-223 dichloride is radioactive and mainly accumulates in the bone. By emitting radiation from nearby areas, the drug aims to inhibit bone metastases. The drug should not be used if additional metastases have formed in the organs. The radiation poses no risk for other people.

If prolongation of life was the primary therapeutic objective and the patients were eligible for docetaxel treatment, the G-BA specified docetaxel in combination with prednisone or prednisolone as appropriate comparator therapy (docetaxel population). However, there were no evaluable data for this comparison. Hence an added benefit of radium-223 is not proven for this subpopulation.

BSC as comparator therapy for the treatment goal "symptom control"

If docetaxel treatment was not an option for the patients or if the primary treatment goal was the relief of symptoms, the so-called "symptom control," and the prevention of complications, the G-BA specified BSC as appropriate comparator therapy (BSC population). BSC means a therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms and improve quality of life. In particular, these include adequate pain therapy, treatment with bisphosphonates and/or radionuclides.

Assessment based on approval study

The benefit assessment of radium-223 compared with BSC was the randomized controlled approval study BC1 06 (ALSYMPCA). 921 patients with an average (median) age of 70 to 71 years participated in this study worldwide. Two thirds of the patients received radium-223 + BSC, the others received placebo + BSC.

The majority of patients included in the study were not eligible for docetaxel because their disease had progressed despite pretreatment with this drug (approximately 57%). It was assumed in the assessment that most of the remaining patients actively decided against docetaxel treatment. The study population was therefore an adequate approximation of the BSC population. Approximately 40% of the patients received concomitant treatment with bisphosphonates.

The BC1 02 study additionally cited by the drug manufacturer was not considered because radium-223 was not used in compliance with its approval in this study.

Uncertain results on side effects and quality of life

Data were available for the following outcomes: overall survival, time to first skeletal-related complication, adverse events and health-related quality of life. However, the results on severe and serious adverse events (e.g. pain), on discontinuation due to such events and on occurrence of diarrhea were uncertain. The data on health-related quality of life presented by the manufacturer were either not evaluable (EQ-5D) or subject to great uncertainty (FACT-P).

Extent of survival advantage depends on age

Patients in the radium-223 arm of the study survived longer than patients in the control group, but the extent of added benefit depends on age: For men younger than 65 years, there was an indication of a major added benefit of radium-223. For patients aged over 65 years, only an indication of a minor added benefit could be determined.

Bone symptoms occurred later

Radium-223 also had advantages for the patients with regards to the burden of disease (morbidity). Bone symptoms occurred considerably later in men who were treated with radium-223 + BSC than under BSC treatment alone. Concomitant treatment with bisphosphonates played a role for the extent of added benefit: For patients with bisphosphonate treatment, there was an indication of a major added benefit, whereas for patients without this concomitant treatment, there was only a hint of a non-quantifiable (no more than considerable) added benefit of radium-223 with BSC compared with BSC.

Fewer side effects in most patients

Most of the patients who were treated with radium-223 also had fewer side effects: With regards to serious/severe side effects, there were no more than indications of lesser harm from radium-223 + BSC compared with BSC with the extent of no more than "minor." This lesser harm was presumably due to side effects caused by an increased use of drugs (e.g. analgesics) in the placebo + BSC group.

This was offset by a hint of considerably greater harm from radium-223 + BSC due to more frequent, but never severe, diarrhea in patients without docetaxel pretreatment. This greater harm did not raise doubts about the overall assessment.

Overall assessment: added benefit only for one patient population

Overall, there was an added benefit in the BSC population, which depended on age and concomitant bisphosphonate treatment: IQWiG determined an indication of a major added benefit of radium-223 + BSC versus BSC as appropriate comparator therapy in patients younger than 65 years and in patients older than 65 years who were treated with bisphosphonate. An indication of a minor added benefit of radium-223 can be derived for patients older than 65 years without concomitant bisphosphonate treatment.

In this overall assessment, the longer overall survival, the delay in the occurrence of bone symptoms and fewer side effects were decisive for the added benefit of radium-223 + BSC compared with BSC.

There were no evaluable data for the docetaxel population. Hence an added benefit of radium-223 is not proven for this subpopulation.


Story Source:

The above story is based on materials provided by Institute for Quality and Efficiency in Health Care. Note: Materials may be edited for content and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Radium-223 dichloride in prostate cancer: Major added benefit for certain patients." ScienceDaily. ScienceDaily, 3 April 2014. <www.sciencedaily.com/releases/2014/04/140403105810.htm>.
Institute for Quality and Efficiency in Health Care. (2014, April 3). Radium-223 dichloride in prostate cancer: Major added benefit for certain patients. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/04/140403105810.htm
Institute for Quality and Efficiency in Health Care. "Radium-223 dichloride in prostate cancer: Major added benefit for certain patients." ScienceDaily. www.sciencedaily.com/releases/2014/04/140403105810.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins